Claims for harm linked to Dupixent

Who can ask about a Dupixent claim?

Start with the drug records and the diagnosis you want checked. Keep the dates of treatment and tests. Ask a lawyer how the law applies to your facts.

The June 2026 transfer order describes claims by people diagnosed with cutaneous T-cell lymphoma, a skin lymphoma, after Dupixent use. It records allegations about causation and warnings. It does not decide that every person who used the drug qualifies for a claim.

For preparation, make a treatment list with the prescribing clinician, why the drug was used, the first and last dates you remember and any gaps. Link each entry to a prescription, pharmacy record or note where you have one. Mark a memory as a memory rather than giving it the weight of a document.

Put diagnosis records and biopsy reports in a separate part of the file. Ask the clinician to explain the diagnosis rather than trying to infer it from a rash or an online photograph. For the legal review, ask which facts are established and which require further medical evidence.

What money could a Dupixent claim bring?

Ask what harm a claim could cover and what evidence is needed. The transfer order is not a payment award. This page gives no personal payout estimate.

Write down the losses you want reviewed and keep the records behind them. Use dates and actual bills where available. Separate confirmed expenses from rough estimates, and ask which parts of the list matter under the law the lawyer is applying.

The JPML decision concerns coordinated work before trial. It neither sets a payment amount for you nor resolves the disputed causal question. A number taken from another drug case would not answer what this record means for your own facts.

If you are shown an offer or estimate, ask what it is based on, which conditions attach and how fees and expenses would affect the amount you keep. Request the explanation in writing. Do not treat an advertising figure as an assessment of your medical record.

Which filing deadline should I check?

Give a lawyer the dates and places in your history. Ask which claim and time limit apply. A court schedule for other cases does not calculate your deadline.

The court’s general guide explains that time limits depend on the claim and governing law. It does not establish a national Dupixent cutoff. Ask the reviewing lawyer what rule it is using and which facts it needs to determine the date.

Prepare a date line with drug use, worsening symptoms, tests and diagnosis. Identify the record supporting each date and mark estimates. Ask whether any earlier filing, representation agreement or release affects a proposed next step, rather than assuming that a new call starts a new time period.

If you already have a lawyer, ask that lawyer about the deadline and the status of the file. Keep letters and notices together. Before signing with a second firm, ask both how the change would be handled and which person is responsible for any pending action.

What does the research show?

Studies report a link between drug use and later skin-lymphoma diagnoses. They do not prove a cause for each patient. Some early cancer signs may be mistaken for eczema.

Jenna Mandel’s team at Thomas Jefferson University compared 19,612 patients treated with dupilumab with 19,612 matched patients who were not. The record-based study found more skin-lymphoma diagnoses in the treated group. Billing-code errors, limited matching and the possibility of an earlier missed cancer diagnosis limit causal inference.

Robert Stuver’s MSK team compared 27 lymphoma patients with prior dupilumab use with 27 matched lymphoma patients without it. It detected no difference in survival or treatment outcomes. This small, selected cancer-center study had limited follow-up and did not test whether the drug causes lymphoma or estimate new-diagnosis risk.

FDA’s table with information as of March 6, 2025 listed a possible skin-lymphoma signal for Dupixent and evaluation of the need for action. That dated entry is not a recall or a finding that the drug caused an individual illness. A current label or later agency decision needs a fresh check.

Ask the clinician how the research relates to the condition for which you were treated. The two studies discussed here involve eczema or patients already diagnosed with lymphoma. Their populations and questions differ, so a result should be read with its design and limits rather than turned into a prediction for every drug user.

Questions about Dupixent and your records

Bring the questions below to your clinician or lawyer. Keep the health question separate from the claim question. Ask for an answer tied to your own records.

Use the answers as a starting point for the conversation. Note what does not match your history and what you still want explained. If someone gives a firm conclusion, ask which record supports it and whether another test or legal check could change it.

How Dupixent (Dupilumab) May Cause Cutaneous T-Cell Lymphoma

Dupixent (dupilumab), a monoclonal antibody manufactured by Regeneron Pharmaceuticals and Sanofi, works by blocking interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. While effective for atopic dermatitis, asthma, and other inflammatory conditions, emerging evidence suggests that this immune pathway modification may impair the body's natural cancer surveillance mechanisms, potentially enabling the development or unmasking of cutaneous T-cell lymphoma (CTCL). A 2024 study of 19,612 patients found a 4.5-fold increased risk of CTCL among Dupixent users compared to controls.

IL-4/IL-13 Pathway Blockade Disrupts Immune Surveillance

Dupilumab binds to the IL-4 receptor alpha subunit, simultaneously blocking IL-4 and IL-13 signaling. These cytokines play critical roles in type 2 immune responses, but they also participate in broader immune regulation. By suppressing the Th2 pathway, dupilumab shifts the immune balance toward Th1/Th17 responses while potentially reducing the immune system's ability to detect and eliminate abnormal T-cell clones in the skin. This altered immune microenvironment may create permissive conditions for malignant T-cell proliferation.

Unmasking of Pre-Existing CTCL Misdiagnosed as Eczema

Early-stage cutaneous T-cell lymphoma (mycosis fungoides) presents with erythematous, scaly patches that are clinically and histopathologically similar to chronic eczema. Patients with undiagnosed early-stage CTCL may be prescribed Dupixent for presumed refractory atopic dermatitis. When Dupixent suppresses the inflammatory component of the skin disease but fails to address the underlying malignancy, the CTCL progresses and becomes clinically apparent. This unmasking phenomenon means some CTCL cases attributed to Dupixent may represent delayed diagnosis enabled by the drug's partial symptomatic control.

Disruption of Anti-Tumor T-Cell Clonal Surveillance

The IL-4/IL-13 axis influences dendritic cell maturation, antigen presentation, and the activation of cytotoxic T-cells that normally eliminate malignant cells. By blocking these pathways, dupilumab may impair the skin's resident immune cells from mounting an effective anti-tumor response against emerging malignant T-cell clones. Published case reports describe CTCL emerging in patients with no prior history of lymphoma after months to years of Dupixent therapy, suggesting a direct immunosuppressive contribution rather than simple unmasking.

Chronic Immune Modulation Alters Skin Microenvironment

Long-term IL-4/IL-13 blockade fundamentally alters the cytokine milieu in the skin. The resulting shift in T-cell subsets, reduced eosinophil recruitment, and modified dendritic cell function create a persistently altered dermal immune environment. Over months or years of continuous therapy, this modified microenvironment may favor the survival and expansion of aberrant T-cell populations that would otherwise be eliminated by normal immune surveillance mechanisms.

• Long-Term Continuous Use in Immunologically Vulnerable Patients: Dupixent is prescribed as an ongoing maintenance therapy, often for years. Patients with severe atopic dermatitis frequently have baseline immune dysregulation, making them particularly susceptible to the consequences of additional immune pathway modification. The cumulative effect of prolonged IL-4/IL-13 blockade on cancer surveillance has not been adequately studied in long-term clinical trials.
• Diagnostic Confusion Between Atopic Dermatitis and Early CTCL: The clinical overlap between refractory eczema and early mycosis fungoides is well-documented in dermatology literature. Patients placed on Dupixent for treatment-resistant eczema may actually harbor undiagnosed CTCL, and the drug's anti-inflammatory effects can mask disease progression until the lymphoma reaches an advanced stage.
• Rapid Expansion of Approved Indications Without Proportionate Safety Monitoring: Dupixent has been approved for progressively broader indications — atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and COPD — exposing millions of patients to long-term IL-4/IL-13 blockade. The post-market safety surveillance infrastructure has not kept pace with this rapid expansion.
• Inadequate Cancer-Specific Endpoints in Clinical Trials: Regeneron's pivotal clinical trials for Dupixent were designed with efficacy endpoints focused on symptom reduction, not long-term oncologic safety. Trial durations of 16-52 weeks were insufficient to detect malignancies with latency periods of years. The 19,612-patient observational study that identified the 4.5x CTCL risk was conducted by independent researchers, not by the manufacturer.
• A 2024 observational study of 19,612 dupilumab-treated patients identified a 4.5-fold increased risk of cutaneous T-cell lymphoma compared to matched controls, representing the largest systematic analysis of this safety signal to date.
• The FDA added CTCL to the Dupixent safety monitoring watchlist in March 2025 following review of post-market adverse event reports and published literature.
• Multiple peer-reviewed case reports and case series published between 2021 and 2025 document CTCL diagnoses in patients receiving dupilumab therapy, with cases spanning both new-onset lymphoma and unmasking of previously occult disease.
• Dermatology professional societies have issued clinical guidance recommending that patients with treatment-resistant eczema undergo skin biopsy to rule out CTCL before initiating dupilumab therapy.

The Dupixent litigation centers on whether Regeneron and Sanofi knew or should have known about the CTCL risk and failed to adequately warn prescribers and patients. The existence of over 300 adverse event reports to the FDA, combined with the independent 19,612-patient study showing 4.5x increased risk, forms the evidentiary foundation for failure-to-warn claims. Plaintiffs allege that earlier and more prominent warnings would have prompted diagnostic workups before drug initiation, potentially preventing CTCL progression in misdiagnosed patients.

Mycosis Fungoides

Mycosis fungoides is the most common subtype of cutaneous T-cell lymphoma, accounting for roughly half of all CTCL diagnoses. The name — which dates to 1806 and has nothing to do with fungal infection — describes the mushroom-like tumors that can develop in advanced stages. What makes mycosis fungoides particularly insidious in the context of Dupixent litigation is its clinical trajectory: it begins as flat, innocuous-looking patches that are virtually indistinguishable from the eczema that Dupixent is prescribed to treat. A dermatologist looking at a Dupixent patient with new red patches has every reason to assume eczema is worsening rather than suspecting a rare lymphoma. This is not a failure of individual physicians — it is a systemic diagnostic trap created by prescribing a drug for a condition that mimics the cancer the drug may cause. Mycosis fungoides progresses through four clinical phases: patch stage (flat, scaly erythematous areas), plaque stage (raised, thickened lesions), tumor stage (dome-shaped nodules that can ulcerate), and disseminated stage (lymph node and visceral involvement). The rate of progression varies enormously — some patients remain in patch stage for decades, while others advance to tumor stage within two to three years. The critical factor for Dupixent plaintiffs is that misdiagnosis during patch stage means the cancer may not be detected until it reaches plaque or tumor stage, when treatment options narrow and survival rates decline sharply.

Flat, oval patches with fine scaling in sun-protected areas

Classic early mycosis fungoides appears as well-circumscribed erythematous patches, often on the buttocks, inner thighs, trunk, and upper arms — areas typically covered by clothing. This bathing-suit distribution differs subtly from eczema but is easily overlooked.

Poikilodermatous changes (mottled pigmentation and telangiectasia)

As patches persist, they develop a characteristic mottled appearance with areas of hyperpigmentation, hypopigmentation, fine wrinkling, and visible small blood vessels — a pattern called poikiloderma that is uncommon in true eczema.

Thick, indurated plaques with annular or serpiginous borders

Plaque-stage mycosis fungoides produces raised, firm lesions that can form ring-shaped or wavy patterns. Unlike eczema plaques, these have a palpable firmness reflecting dense dermal infiltration by malignant T-cells.

Dome-shaped skin tumors prone to ulceration

Tumor-stage disease produces nodular masses that can reach several centimeters in diameter, ulcerate centrally, and become superinfected. This stage is unmistakable clinically but represents late-stage disease with significantly worse outcomes.

Alopecia in patches overlying active disease

Hair loss within and around mycosis fungoides patches — particularly on the scalp, eyebrows, or body — is a diagnostic clue that the process is not simple eczema. Folliculotropic mycosis fungoides specifically targets hair follicles and carries a worse prognosis.

Leonine facies in advanced disease

In rare advanced cases, diffuse facial infiltration by malignant T-cells produces thickened, rugose facial skin resembling a lion's face — a dramatic presentation that is pathognomonic for advanced CTCL but occurs only in late-stage disease.

• Dupixent use with IL-4/IL-13 blockade potentially unmasking or promoting T-cell clonal proliferation
• Chronic atopic dermatitis itself — patients with longstanding AD may have baseline immune dysregulation affecting T-cell surveillance
• Age over 55 — median age at mycosis fungoides diagnosis is 55 to 60 years
• Male sex — approximately 1.5 to 2 times more common in men than women
• Prior history of persistent dermatitis unresponsive to multiple treatments — may represent undiagnosed early MF misclassified as eczema
• Clinical recognition of skin lesions inconsistent with eczema response — key trigger for biopsy in Dupixent users
• Multiple punch biopsies from active lesions including oldest and most infiltrated-appearing areas
• Histopathology showing band-like lymphocytic infiltrate with epidermotropism and Pautrier microabscesses
• Immunophenotyping by immunohistochemistry: CD3+, CD4+, CD8-, with loss of CD7 and/or CD26
• T-cell receptor gene rearrangement studies (PCR-based) to confirm monoclonal T-cell population
• Complete blood count with Sezary cell preparation to rule out leukemic involvement
• PET-CT scan for staging in patients with plaque-stage or higher disease
• Topical mechlorethamine (Valchlor) gel for patch-stage disease — FDA-approved first-line skin-directed therapy
• Narrowband UVB phototherapy for thin patches; PUVA (psoralen + UVA) for thicker patches and plaques
• Topical and intralesional corticosteroids for localized symptomatic relief
• Localized radiation therapy for individual tumors or refractory plaques
• Oral bexarotene (Targretin) — a retinoid X receptor agonist for refractory or progressive disease
• Mogamulizumab (Poteligeo) — anti-CCR4 antibody for relapsed MF after at least one prior systemic therapy
• Low-dose methotrexate for skin-limited disease when other options are inadequate

Mycosis fungoides behaves very differently depending on when it is caught. A patient diagnosed at patch stage can often be managed for years or decades with skin-directed therapies alone, maintaining a quality of life that is dramatically better than what faces patients diagnosed at tumor stage. The crux of the Dupixent litigation is that the drug creates conditions in which early mycosis fungoides is systematically missed — not because doctors are negligent, but because the cancer presents as the disease the drug is supposed to treat. Every month of delayed diagnosis is a month in which the cancer can progress from a treatable skin condition to a life-threatening systemic malignancy.

• Cutaneous Lymphoma Foundation (clfoundation.org) — the leading U.S. nonprofit for MF/CTCL patients
• MyHealth.Alberta.ca — evidence-based MF patient education
• National Comprehensive Cancer Network (NCCN) — treatment guidelines for primary cutaneous lymphomas
• PatientsLikeMe — online community for CTCL patients sharing treatment experiences

Regeneron and Sanofi: Corporate Accountability for Dupixent Safety Failures

Dupixent (dupilumab) is jointly developed and commercialized by Regeneron Pharmaceuticals and Sanofi under a global collaboration agreement. As CTCL safety concerns mount, both companies face scrutiny over whether their post-market surveillance and prescriber communications adequately addressed emerging lymphoma signals that were visible in their own pharmacovigilance data.

Prioritizing Revenue Growth Over Long-Term Safety Monitoring

Plaintiffs allege that Regeneron and Sanofi pursued aggressive indication expansion and direct-to-consumer marketing while failing to invest proportionate resources in post-market cancer surveillance. The 19,612-patient study that identified the 4.5x CTCL risk was conducted by independent researchers — not by the manufacturer — despite Regeneron and Sanofi having access to their own pharmacovigilance databases that contained the same safety signal.

• Regeneron and Sanofi expanded Dupixent to six indications between 2017 and 2024 without conducting manufacturer-sponsored long-term studies specifically designed to evaluate oncologic safety endpoints.
• Independent researchers, not the manufacturer, conducted the landmark 19,612-patient study that quantified the CTCL risk — raising questions about whether Regeneron's pharmacovigilance function was adequately analyzing its own adverse event data.
• Direct-to-consumer television advertising for Dupixent did not mention any cancer or lymphoma risk, despite accumulating FAERS reports that were known to both companies.
• Regeneron executives publicly characterized the CTCL signal as likely representing diagnostic unmasking rather than drug-induced lymphoma, a position that plaintiff experts argue minimizes a serious safety concern to protect commercial interests.

The emerging CTCL litigation directly challenges whether these companies prioritized revenue growth and indication expansion over the patient safety investment needed to detect and communicate a serious cancer risk that independent researchers ultimately identified.

Dupixent CTCL Lawsuit Filing Deadlines — MDL No. 3180 and State SOL Guide

On June 4, 2026, the JPML grouped federal Dupixent skin-lymphoma cases in MDL No. 3180 in the District of New Jersey before Judge Zahid N. Quraishi. Because Dupixent-linked CTCL is a recently discovered injury — one that was systematically masked by the drug's intended use for skin conditions — the discovery rule applies in most jurisdictions. That means the statute of limitations clock typically starts when a plaintiff was diagnosed with CTCL (or when they reasonably should have connected the diagnosis to Dupixent), not when they first took the drug. But discovery rules have limits, and defendants will argue that publicly available safety signals should have put patients on notice earlier. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.

Why the Discovery Rule Is Critical for Dupixent Claimants

Dupixent presents a uniquely deceptive diagnostic problem. The drug is prescribed for eczema — a condition that looks almost identical to early-stage cutaneous T-cell lymphoma. For years, dermatologists mistook CTCL symptoms in Dupixent patients for eczema flares or treatment resistance, delaying cancer diagnoses by months or even years. This diagnostic confusion is precisely the kind of scenario the discovery rule was designed to address. In states that apply the discovery rule, the statute of limitations begins when the plaintiff knew or should have known that (1) they had CTCL and (2) Dupixent may have caused or contributed to it. Given that the first peer-reviewed study linking Dupixent to CTCL was published in 2024 and the FDA opened its formal investigation in September 2025, many people diagnosed with CTCL after Dupixent use may still be within their filing windows. Regeneron and Sanofi may argue that earlier safety signals — including FAERS reports and the March 2025 FDA watchlist placement — should have triggered a duty to investigate. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you. It also helps to keep pharmacy records, injection logs, dermatology visit notes, and biopsy reports must be collected and secured before medical record retention periods expire.

A 52-year-old woman in Georgia used Dupixent for atopic dermatitis from 2019 to 2023. In 2024, a dermatologist biopsied a persistent rash that had not responded to Dupixent — pathology confirmed mycosis fungoides (CTCL). She consulted an attorney in early 2026.

Georgia has a two-year personal injury statute of limitations with a discovery rule. Her clock started when the biopsy confirmed CTCL in 2024 — not when she first took Dupixent in 2019. She is within the filing window. Her attorney filed in federal court, and her case was transferred to MDL No. 3180.

A 38-year-old father in Texas was prescribed Dupixent for moderate-to-severe asthma in 2020. In late 2025, he was diagnosed with Sezary syndrome — the aggressive blood-borne form of CTCL — after months of unexplained skin lesions his pulmonologist attributed to allergic reactions.

Texas applies a two-year statute of limitations with a discovery rule for latent injury claims. His diagnosis in late 2025 starts the clock. Sezary syndrome is the most aggressive CTCL subtype. His attorney preserved Dupixent pharmacy records, injection site photographs, pulmonology and dermatology notes, and the pathology report showing malignant T-cells in peripheral blood. No trial dates have been set in the MDL.

The discovery rule protects most Dupixent-CTCL claimants who were diagnosed in 2024 or later, but discovery rules have limits. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.

Filing deadlines vary by state and depend on individual circumstances including date of diagnosis and date of discovery of the connection to Dupixent. This table provides general guidance and is not legal advice. An attorney can evaluate the specific deadlines that apply to your case.